Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson's Disease in Rats.
6-Hydroxydopamine
Acetylcholinesterase
Amantadine
L-DOPA-induced dyskinesia
Parkinson’s disease
Tyrosine
Journal
Journal of molecular neuroscience : MN
ISSN: 1559-1166
Titre abrégé: J Mol Neurosci
Pays: United States
ID NLM: 9002991
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
21
12
2021
accepted:
30
12
2021
pubmed:
30
1
2022
medline:
9
4
2022
entrez:
29
1
2022
Statut:
ppublish
Résumé
The neuroprotective capacity of newly synthesized amantadine derivative tyrosinyl-amantadine (Tyr-Am) with expected antiparkinsonian properties was evaluated in a 6-hydroxydopamine (6-OHDA) model of Parkinson's disease. Male Wistar rats were divided into the following groups: sham-operated (SO), striatal 6-OHDA-lesioned control group, 6-OHDA-lesioned rats pretreated for 6 days with Tyr-Am (16 mg/kg administered intraperitoneally, i.p.), and 6-OHDA-lesioned rats pretreated for 6 days with amantadine (40 mg/kg i.p.), used as a referent. On the first, second and third week post-lesion, the animals were subjected to some behavioral tests (apomorphine-induced rotation, rotarod, and passive avoidance test). The acetylcholinesterase (AChE) activity and key oxidative stress parameters including lipid peroxidation levels (LPO) and superoxide dismutase (SOD) were measured in brain homogenates. The results showed that the neuroprotective effect of Tyr-Am was comparable to that of amantadine, improving neuromuscular coordination and learning and memory performance even at a 2.5-fold lower dose. Tyr-Am demonstrated significant antioxidant properties via decreased LPO levels but had no effect on AChE activity. We can conclude that the newly synthesized amantadine derivative Tyr-Am demonstrated significant antiparkinsonian activity in a 6-OHDA experimental model.
Identifiants
pubmed: 35091981
doi: 10.1007/s12031-021-01964-x
pii: 10.1007/s12031-021-01964-x
doi:
Substances chimiques
Antiparkinson Agents
0
Oxidopamine
8HW4YBZ748
Amantadine
BF4C9Z1J53
Acetylcholinesterase
EC 3.1.1.7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
900-909Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G et al (2011) Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias. Brain 134(4):979–986. https://doi.org/10.1093/brain/awr028
doi: 10.1093/brain/awr028
pubmed: 21371994
Bak IJ, Hassler R, Kim JS, Kataoka K (1972) Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioral changes. J Neural Transm 33(1):45–61. https://doi.org/10.1007/BF01244727
doi: 10.1007/BF01244727
pubmed: 4674484
Beani L, Bianchi C (1973) Effect of amantadine on cerebral acetyl-choline release and content in the guinea pig. Neuropharmacology 12(4):283–289. https://doi.org/10.1016/0028-3908(73)90087-7
doi: 10.1016/0028-3908(73)90087-7
pubmed: 4703874
Bido S, Marti M, Morari M (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J neurochem 118(6):1043–1055. https://doi.org/10.1111/j.1471-4159.2011.07376.x
doi: 10.1111/j.1471-4159.2011.07376.x
pubmed: 21740438
Binder M, Hirokawa N, Windhorst U (2009) Passive Avoidance Learning. In: Binder M, Hirokawa N, Windhorst U (eds) Encyclopedia of Neuroscience. Springer, Berlin, p 3093
doi: 10.1007/978-3-540-29678-2
Blandini F, Armentero MT, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14:S124–S129. https://doi.org/10.1016/j.parkreldis.2008.04.015
doi: 10.1016/j.parkreldis.2008.04.015
pubmed: 18595767
Blanpied TA, Boeckman FA, Aizenman E, Johnson JW (1997) Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 77(1):309–323. https://doi.org/10.1152/jn.1997.77.1.309
doi: 10.1152/jn.1997.77.1.309
pubmed: 9120573
Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25(13):3312–3322. https://doi.org/10.1523/JNEUROSCI.4262-04.2005
doi: 10.1523/JNEUROSCI.4262-04.2005
pubmed: 15800186
pmcid: 6724906
Bortolanza M, Bariotto-dos-Santos KD, dos-Santos-Pereira M, da-Silva CA, Del-Bel E (2016) Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson’s disease. Neurotox Res 30(1):88–100. https://doi.org/10.1007/s12640-016-9618-4
doi: 10.1007/s12640-016-9618-4
pubmed: 27053252
Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134. https://doi.org/10.1007/s00441-004-0956-9
doi: 10.1007/s00441-004-0956-9
pubmed: 15338272
Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20(8):919–931. https://doi.org/10.1002/mds.20612
doi: 10.1002/mds.20612
pubmed: 16007614
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A (2008a) Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat Disord 14:S154–S158. https://doi.org/10.1016/j.parkreldis.2008.04.021
doi: 10.1016/j.parkreldis.2008.04.021
pubmed: 18579429
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A (2008b) Serotonin–dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res 172:465–478. https://doi.org/10.1016/S0079-6123(08)00922-9
doi: 10.1016/S0079-6123(08)00922-9
pubmed: 18772046
Dabbeni-Sala F, Santo S, Franceschini D, Skaper SD, Giusti P (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15(1):164–170. https://doi.org/10.1096/fj.00-0129com
doi: 10.1096/fj.00-0129com
pubmed: 11149904
Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents—preclinical studies. Neurosci Biobehav Rev 21(4):455–468. https://doi.org/10.1016/S0149-7634(96)00037-1
doi: 10.1016/S0149-7634(96)00037-1
pubmed: 9195603
Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG (2000) Alterations in subunit expression, composition, and phosphorylation of striataln-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson’s disease. Mol Pharmacol 57(2):342–352
pubmed: 10648644
Duty S (2012) Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson’s disease. CNS drugs 26(12):1017–1032. https://doi.org/10.1007/s40263-012-0016-z
doi: 10.1007/s40263-012-0016-z
pubmed: 23114872
Ellman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7(2):88–95. https://doi.org/10.1016/0006-2952(61)90145-9
doi: 10.1016/0006-2952(61)90145-9
pubmed: 13726518
Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C (2006) Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol 69(3):805–812
doi: 10.1124/mol.105.016667
Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G et al (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26(11):2914–2922. https://doi.org/10.1523/JNEUROSCI.5326-05.2006
doi: 10.1523/JNEUROSCI.5326-05.2006
pubmed: 16540568
pmcid: 6673976
Gelenberg AJ, Gibson CJ (1984) Tyrosine for the treatment of depression. Nutrition and health 3(3):163–173. https://doi.org/10.1177/026010618400300305
doi: 10.1177/026010618400300305
pubmed: 6443584
Gheibi S, Aboutaleb N, Khaksari M, Kalalian-Moghaddam H, Vakili A, Asadi Y et al (2014) Hydrogen sulfide protects the brain against ischemic reperfusion injury in a transient model of focal cerebral ischemia. J Mol Neurosci 54(2):264–270. https://doi.org/10.1007/s12031-014-0284-9
doi: 10.1007/s12031-014-0284-9
pubmed: 24643521
González-Hernández T, Barroso-Chinea P, de la Cruz Muros I, del Mar Pérez-Delgado M, Rodríguez M (2004) Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J Comp Neurol 479(2):198–215. https://doi.org/10.1002/cne.20323
doi: 10.1002/cne.20323
pubmed: 15452855
Greenamyre JT, O’Brien CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson’s disease. Arch Neurol 48(9):977–981. https://doi.org/10.1001/archneur.1991.00530210109030
doi: 10.1001/archneur.1991.00530210109030
pubmed: 1835370
Growdon JH, Melamed E, Logue M, Hefti F, Wurtman RJ (1982) Effects of oral L-tyrosine administration of CSF tyrosine and homovanillic acid levels in patients with Parkinson’s disease. Life Sci 30(10):827–832. https://doi.org/10.1016/0024-3205(82)90596-3
doi: 10.1016/0024-3205(82)90596-3
pubmed: 6175872
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev 65(1):171–222
doi: 10.1124/pr.111.005678
Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav Brain Res 162(1):1–10. https://doi.org/10.1016/j.bbr.2005.02.023
doi: 10.1016/j.bbr.2005.02.023
pubmed: 15922062
Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 20(S11):S11–S16. https://doi.org/10.1002/mds.20458
doi: 10.1002/mds.20458
pubmed: 15822109
Jarvik ME, Kopp R (1967) An improved one-trial passive avoidance learning situation. Psychol Rep 21(1):221–224. https://doi.org/10.2466/pr0.1967.21.1.221
doi: 10.2466/pr0.1967.21.1.221
pubmed: 6078370
Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665–677. https://doi.org/10.1038/nrn2471
doi: 10.1038/nrn2471
pubmed: 18714325
Kalda A, Herm L, Rinken A, Zharkovsky A, Chen JF (2009) Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice. Behav Brain Res 202(2):232–237. https://doi.org/10.1016/j.bbr.2009.03.037
doi: 10.1016/j.bbr.2009.03.037
pubmed: 19463706
Kalia LV, Brotchie JM, Fox SH (2013) Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. Mov Disord 28(2):131–144. https://doi.org/10.1002/mds.25273
doi: 10.1002/mds.25273
pubmed: 23225267
Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol: Molecular Pharmacology 206(4):297–300. https://doi.org/10.1016/0922-4106(91)90113-V
doi: 10.1016/0922-4106(91)90113-V
Lazarova M, Popatanasov A, Klissurov R, Stoeva S, Pajpanova T, Kalfin R, Tancheva L (2018) Preventive effect of two new neurotensin analogues on Parkinson’s disease rat model. J Mol Neurosci 66(4):552–560. https://doi.org/10.1007/s12031-018-1171-6
doi: 10.1007/s12031-018-1171-6
pubmed: 30374780
Lemoine P, Robelin N, Sebert P, Mouret J (1989) L-tyrosine: a long term treatment of Parkinson’s disease. C R Acad Sci III 309(2):43–47
pubmed: 2502304
Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA (2017) Increased oxidative stress markers in cerebrospinal fluid from healthy subjects with Parkinson’s disease-associated LRRK2 gene mutations. Front Aging Neurosci 9:89–97. https://doi.org/10.3389/fnagi.2017.00089
doi: 10.3389/fnagi.2017.00089
pubmed: 28420983
pmcid: 5376564
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
doi: 10.1016/S0021-9258(19)52451-6
Luginger E, Wenning GK, Bösch S, Poewe W (2000) Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 15(5):873–878. https://doi.org/10.1002/1531-8257(200009)15:5%3c873::AID-MDS1017%3e3.0.CO;2-I
doi: 10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I
pubmed: 11009193
Lupp A, Kerst S, Karge E, Quack G, Klinger W (1998) Investigation on possible antioxidative properties of the NMDA-receptor antagonists ketamine, memantine, and amantadine in comparison to nicanartine in vitro. Exp Toxicol Pathol 50(4–6):501–506. https://doi.org/10.1016/S0940-2993(98)80041-9
doi: 10.1016/S0940-2993(98)80041-9
pubmed: 9784030
Lupp A, Lücking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263(2):717–724
pubmed: 1359111
Macchio GJ, Ito V, Sahgal V (1993) Amantadine-induced coma. Arch Phys Med Rehabil 74(10):1119–1120. https://doi.org/10.1016/0003-9993(93)90072-I
doi: 10.1016/0003-9993(93)90072-I
pubmed: 8215867
Majláth Z, Vécsei L (2014) NMDA antagonists as Parkinson’s disease therapy: disseminating the evidence. Neurodegener Dis Manag 4(1):23–30. https://doi.org/10.2217/nmt.13.77
doi: 10.2217/nmt.13.77
pubmed: 24640976
Marvanova M, Nichols CD (2007) Identification of neuroprotective compounds of Caenorhabditis elegans dopaminergic neurons against 6-OHDA. J Mol Neurosci 31(2):127–137. https://doi.org/10.1385/JMN/31:02:127
doi: 10.1385/JMN/31:02:127
pubmed: 17478886
McGeer PL, Grewaal DS, McGeer EG (1974) Influence of noncholinergic drugs on rat striatal acetylcholine levels. Brain Res 80(2):211–217. https://doi.org/10.1016/0006-8993(74)90685-4
doi: 10.1016/0006-8993(74)90685-4
pubmed: 4154064
Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P et al (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10(5):377–393. https://doi.org/10.1038/nrd3430
doi: 10.1038/nrd3430
pubmed: 21532567
Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56(11):1383–1386. https://doi.org/10.1001/archneur.56.11.1383
doi: 10.1001/archneur.56.11.1383
pubmed: 10555659
Morin N, Di Paolo T (2014) Pharmacological treatments inhibiting levodopa-induced dyskinesias in MPTP-lesioned monkeys: brain glutamate biochemical correlates. Front Neurol 5:144–152. https://doi.org/10.3389/fneur.2014.00144
doi: 10.3389/fneur.2014.00144
pubmed: 25140165
pmcid: 4122180
Nakano I, Hirano A (1984) Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol 15(5):415–418. https://doi.org/10.1002/ana.410150503
doi: 10.1002/ana.410150503
pubmed: 6732189
Nayebi AM, Rad SR, Saberian M, Azimzadeh S, Samini M (2010) Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT 1A receptors in rats. Pharmacol Rep 62(2):258–264. https://doi.org/10.1016/S1734-1140(10)70264-4
doi: 10.1016/S1734-1140(10)70264-4
pubmed: 20508280
Nicola SM, Surmeier DJ, Malenka RC (2000) Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 23(1):185–215. https://doi.org/10.1146/annurev.neuro.23.1.185
doi: 10.1146/annurev.neuro.23.1.185
pubmed: 10845063
Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA (2009) Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neuroscience 159(3):927–935. https://doi.org/10.1016/j.neuroscience.2009.01.034
doi: 10.1016/j.neuroscience.2009.01.034
pubmed: 19302833
Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W et al (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34(10):1239–1258. https://doi.org/10.1016/0028-3908(95)00092-K
doi: 10.1016/0028-3908(95)00092-K
pubmed: 8570022
Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates. Elsevier, New York
Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA et al (1985) Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 48(5):413–421. https://doi.org/10.1136/jnnp.48.5.413
doi: 10.1136/jnnp.48.5.413
pubmed: 3998751
pmcid: 1028327
Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R (2018) Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. Braz J Psychiatry 40(4):449–458. https://doi.org/10.1590/1516-4446-2017-2393
doi: 10.1590/1516-4446-2017-2393
pubmed: 29898194
pmcid: 6899375
Roghani M, Niknam A, Jalali-Nadoushan MR, Kiasalari Z, Khalili M, Baluchnejadmojarad T (2010) Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull 82(5–6):279–283. https://doi.org/10.1016/j.brainresbull.2010.06.004
doi: 10.1016/j.brainresbull.2010.06.004
pubmed: 20558255
Rozas G, Guerra MJ, Labandeira-Garcıa JL (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Protoc 2(1):75–84. https://doi.org/10.1016/S1385-299X(97)00034-2
doi: 10.1016/S1385-299X(97)00034-2
Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330(1):227–235
doi: 10.1124/jpet.108.150425
Sachs C, Jonsson G (1975) Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 24(1):1–8. https://doi.org/10.1016/0006-2952(75)90304-4
doi: 10.1016/0006-2952(75)90304-4
pubmed: 1092302
Schwarting RK, Huston JP (1997) Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. Neurotoxicology 18(3):689–708
pubmed: 9339817
Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL (1987) Amantadine and motor fluctuations in chronic Parkinson’s disease. Clin Neuropharmacol 10(6):522–526
doi: 10.1097/00002826-198712000-00003
Shapiro RM, Glick SD, Camarota NA (1987) A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res 426(2):323–331. https://doi.org/10.1016/0006-8993(87)90885-7
doi: 10.1016/0006-8993(87)90885-7
pubmed: 2446711
Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson’s disease. Neurotox Res 11(3–4):151–167. https://doi.org/10.1007/BF03033565
doi: 10.1007/BF03033565
pubmed: 17449457
Stankova I, Lazarova M, Chayrov R, Popatanasov A, Tancheva L, Kalfin R (2021) Newly synthesized amantadine derivative: safety and neuropharmacological activity. Farmacia 69(6):1112–1119. https://doi.org/10.31925/farmacia.2021.6.14
Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry 75(1):141–143
doi: 10.1136/jnnp.2004.036558
Toulorge D, Schapira AH, Hajj R (2016) Molecular changes in the postmortem parkinsonian brain. J Neurochem 139:27–58. https://doi.org/10.1111/jnc.13696
doi: 10.1111/jnc.13696
pubmed: 27381749
van Spronsen FJ, van Dijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, Heymans HS (1996) Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr 64(6):916–921. https://doi.org/10.1093/ajcn/64.6.916
doi: 10.1093/ajcn/64.6.916
pubmed: 8942417
Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P et al (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 25(10):1357–1363. https://doi.org/10.1002/mds.23034
doi: 10.1002/mds.23034
pubmed: 20198649
Wood DR, Reimherr FW, Wender PH (1985) Amino acid precursors for the treatment of attention deficit disorder, residual type. Psychopharmacol Bull 21(1):146–149
pubmed: 3885291
Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL (1989) The pedunculopontine nucleus in Parkinson’s disease. Ann Neurol 26(1):41–46. https://doi.org/10.1002/ana.410260106
doi: 10.1002/ana.410260106
pubmed: 2549845